NYU Conference on Ibogaine Nov 5-6, 1999

Drug Policy Seminars

The Lindesmith Center

• Thursday, January 8, 4pm
  Evolving Drug User Services: A Client-Centered Approach to Maintenance Treatment
• Thursday, January 22, 4pm
  Psychedelics and Psychotherapy
• Monday, February 9, 4pm
  Harm Reduction Case Management for Drug Users
• Tuesday, February 24, 4pm
  Pregnant and Parenting Women Who Use Drugs
• Monday, March 2, 4pm
  Ibogaine Treatment

Thursday, January 8, 4pm

Reda Sobky, MD, Ph.D., analyzes past mistakes and current opportunities in the treatment of heroin addiction with methadone and other medications. Sobky, founder of the client-oriented harm reduction programs, Fort Help and Humanistic Alternatives to Addiction in California, examines how and why renewed government interest in opiate agonist treatment can lead to liberalization of maintenance regulations.

Thursday, January 22, 4pm

Myron Stolaroff and Richard Yensen, Ph.D., examine applications of psychedelics to psychotherapy and substance abuse treatment. Stolaroff, founder of The International Center for Advanced Study in Menlo Park, California, and author of The Secret Chief: Conversations with a Pioneer of the Underground Psychedelic Therapy Movement and Thanatos to Eros, analyzes uses of psychedelics in therapy based on his past research and experience as an elder in the field of psychedelic exploration. Yensen, director of the Orenda Institute where he is the co-holder of a research protocol for the use of LSD in psychotherapy, discusses ongoing scientific investigations.

Monday, February 9, 4pm

Stuart Fisk, RN, Stacey Rubin, and Kelly McGowan sketch a model for harm reduction case management. Fisk, based at the Pittsburgh AIDS Education and Training Center and a member of the Harm Reduction Working Group, provides strategies for engaging HIV+ drug users in medical services. Rubin, Director of Harm Reduction at Streetwork Project, Victim Services, and a member of the Harm Reduction Working Group, describes case management with street-based drug-using youth and the utilization of holistic health services. McGowan, Director of Harm Reduction and Transgender Services at the Positive Health Project, examines networking and co-supervision possibilities among harm reduction-oriented case managers serving active drug users. This seminar is moderated by Sara Kershnar, Director of Education and Training at the Harm Reduction Coalition.

Tuesday, February 24, 4pm

Stephen Kandall, MD, Marsha Rosenbaum, Ph.D., and Carol E. Tracy, Esq., examine the complex medical, social, and political issues of pregnant and parenting women who use drugs. Kandall, Chief of Neonatology at Beth Israel Medical Center, Professor of Pediatrics at Albert Einstein College of Medicine, and author of Substance and Shadow: Women and Addiction in the United States (Harvard University Press), describes his clinical experience with drug-exposed babies and implications for medical and public policies. Rosenbaum, Director of the San Francisco office of the Lindesmith Center and co-author, with Dr. Sheigla B. Murphy, of Wayward Wombs: Pregnancy and Drug Use (working title, Rutgers University Press), analyzes problems and solutions in the lives of pregnant and parenting women who use drugs. Carol E. Tracy, Esq., Executive Director of the Women's Law Project in Philadelphia, assess opportunities for community and legal activism on these issues.

Monday, March 2, 1998, 4pm

Ibogaine Treatment

Ken Alper, MD, Ph.D., Geerte Frenken, and Howard Lotsof examine the feasibility and effectiveness of ibogaine in treating chemical dependence. Alper, assistant professor of psychology and neurology at New York University Medical Center, offers a possible model of ibogaine's action based on evidence of its effectiveness in treating cocaine dependence. Frenken, founder and director of International Addicts Self-Help and a researcher with National Development Research Institute, stresses the importance of a comprehensive approach to ibogaine treatment. Lotsof, president of NDA International and the first to discover ibogaine's utility in treating chemical dependence, examines the history and politics of ibogaine.

Current Location

All are welcome, but seating is limited.
Please call The Lindesmith Center/Drug Policy Foundation at (212) 548-0695
or email nyc@drugpolicy.org to reserve a place.